登陆
当前位置: 首页 >> 检索结果

结果排序

文献格式

出版时间

出版类型

出版语言
共有 83919 条符合本次的查询结果， 用时 4.6468371 秒

1841. Black Maternal Mortality Remains Disproportionately High.

作者: Samantha Anderer.
来源: JAMA. 2025年333卷15期1285页

1842. Revising US MMR Vaccine Recommendations Amid Changing Domestic Risks.

作者: Benjamin Rader.;Rochelle P Walensky.;Wesley S Rogers.;John S Brownstein.
来源: JAMA. 2025年333卷14期1201-1202页

1843. Study Finds AI Can Quickly Prescreen Patients for Clinical Trials, Speeding Enrollment.

作者: Yulin Hswen.;Nora Collins.
来源: JAMA. 2025年333卷15期1275-1277页

1844. Amid Texas Measles Outbreak, Clinicians Struggle to Offset Increasing Vaccine Hesitancy.

作者: Kate Schweitzer.
来源: JAMA. 2025年333卷15期1278-1281页

1845. Amid Decreasing Infant Mortality, Sleep-Related Infant Deaths Are on the Rise.

作者: Linda Rodgers.
来源: JAMA. 2025年333卷15期1282-1284页

1846. Peanut Allergy Trial Shows Sustained Tolerance With Gradual Exposure.

作者: Samantha Anderer.
来源: JAMA. 2025年333卷15期1285-1286页

1847. Semaglutide Shows Promise in Reducing Alcohol Cravings.

作者: Samantha Anderer.
来源: JAMA. 2025年333卷15期1285页

1848. FDA Approves First Fast-Acting Insulin Biosimilar for Diabetes.

作者: Samantha Anderer.
来源: JAMA. 2025年333卷15期1285页

1849. Certain Diabetes Medications May Help Lower COPD Exacerbation Risk.

作者: Samantha Anderer.
来源: JAMA. 2025年333卷15期1286页

1850. Study: Bleeding Risk With Some Blood Thinners Similar to Aspirin.

作者: Samantha Anderer.
来源: JAMA. 2025年333卷15期1285页

1851. Curative Application of Immunotherapy in Untreated Head and Neck and Nasopharynx Cancer.

作者: Marshall Posner.
来源: JAMA. 2025年333卷18期1584-1585页

1852. High-Intensity vs Low-Intensity Noninvasive Positive Pressure Ventilation and Need for Endotracheal Intubation-Reply.

作者: Zujin Luo.;Yichong Li.;Zhixin Cao.
来源: JAMA. 2025年333卷14期1262-1263页

1853. Incorrect Data Sharing Statement.

来源: JAMA. 2025年333卷14期1263页

1854. Attributes of a Rejected Manuscript.

来源: JAMA. 2025年333卷14期1266页

1855. What Is Dialysis?

作者: Rebecca Voelker.
来源: JAMA. 2025年333卷19期1752页

1856. High-Intensity vs Low-Intensity Noninvasive Positive Pressure Ventilation and Need for Endotracheal Intubation.

作者: Joseph R Shiber.
来源: JAMA. 2025年333卷14期1262页

1857. Fireflies.

作者: Julia L McDonald.
来源: JAMA. 2025年333卷14期1265页

1858. Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.

作者: Robert Haddad.;Jérôme Fayette.;Maria Teixeira.;Kumar Prabhash.;Ricard Mesia.;Andrzej Kawecki.;Arunee Dechaphunkul.;José Dinis.;Ye Guo.;Muneyuki Masuda.;Ching-Yun Hsieh.;Maria Grazia Ghi.;Claudia Vaz de Melo Sette.;Kevin Harrington.;Makoto Tahara.;Nabil F Saba.;Agnes Lau.;Tao Jiang.;Yibing Yan.;Marcus Ballinger.;Monika Kaul.;Christina Matheny.;Vaikunth Cuchelkar.;Deborah J Wong.
来源: JAMA. 2025年333卷18期1599-1607页
Treating locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) involves any combination of surgery, radiation, and chemotherapy, followed by routine monitoring for local recurrence or distant metastases. Given the poor patient outcomes, a significant unmet clinical need for improved treatment options remains.

1859. My Turban and Tenacity.

作者: Udhayvir Singh Grewal.
来源: JAMA. 2025年333卷14期1207-1208页

1860. Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical Trial.

作者: Ye-Lin Liang.;Xu Liu.;Liang-Fang Shen.;Guang-Yuan Hu.;Guo-Rong Zou.;Ning Zhang.;Chuan-Ben Chen.;Xiao-Zhong Chen.;Xiao-Dong Zhu.;Ya-Wei Yuan.;Kun-Yu Yang.;Feng Jin.;Wei-Han Hu.;Fang-Yun Xie.;Ying Huang.;Fei Han.;Ling-Long Tang.;Yan-Ping Mao.;Li-Xia Lu.;Rui Sun.;Yu-Xiang He.;Yang-Ying Zhou.;Guo-Xian Long.;Jie Tang.;Lu-Si Chen.;Jing-Feng Zong.;Ting Jin.;Ling Li.;Jie Lin.;Jing Huang.;Xiu-Yun Gong.;Guan-Qun Zhou.;Lei Chen.;Wen-Fei Li.;Yu-Pei Chen.;Cheng Xu.;Li Lin.;Shao-Hui Huang.;Sai-Wei Huang.;Ya-Qin Wang.;Cheng-Long Huang.;Hui-Xia Feng.;Min Hou.;Chun-Hua Chen.;Su-Fen Zheng.;Ying-Qing Li.;Shu-Bin Hong.;Yu-Sheng Jie.;Hao Li.;Jing-Ping Yun.;Sheng-Bing Zang.;Song-Ran Liu.;Qing-Guang Lin.;Hao-Jiang Li.;Li Tian.;Li-Zhi Liu.;Hong-Yun Zhao.;Ji-Bin Li.;Ai-Hua Lin.;Na Liu.;Yuan Zhang.;Rui Guo.;Jun Ma.;Ying Sun.
来源: JAMA. 2025年333卷18期1589-1598页
Approximately 20% to 30% of patients with locoregionally advanced nasopharyngeal carcinoma (NPC) experience disease relapse despite definitive chemoradiotherapy. The programmed cell death 1 (PD-1) blockade camrelizumab has demonstrated considerable value in recurrent or metastatic NPC, while its role in locoregionally advanced NPC is unclear.
共有 83919 条符合本次的查询结果， 用时 4.6468371 秒